menu
    • menu
    [{"orgOrder":0,"company":"Essity","sponsor":"Abigo Medical AB","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Dialkylcarbamoylchloride","moa":"||Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Essity","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essity \/ Essity","highestDevelopmentStatusID":"15","companyTruncated":"Essity \/ Essity"},{"orgOrder":0,"company":"Essity","sponsor":"Essity","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Copper","moa":"||Amyloid-beta precursor protein; Adenosylhomocysteinase; Histone H2B type 1-C\/E\/F\/G\/I; Glyceraldehyde-3-phosphate dehydrogenase; Nucleoside diphosphate kinase A; Histone H1.4; Peroxiredoxin-1; Protein S100-A8; Small ribosomal subunit protein uS2; Acti","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Essity","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essity \/ Essity","highestDevelopmentStatusID":"9","companyTruncated":"Essity \/ Essity"}]

    Find Clinical Drug Pipeline Developments & Deals by Essity

    Menu

    Essity

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Essity

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Essity

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Recipient : Hospital Israelita Albert Einstein

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : Copper,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Hospital Israelita Albert Einstein

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Essity

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Essity

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dialkylcarbamoylchloride,Inapplicable

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Recipient : Abigo Medical AB

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Essity Acquires 75% of the Medical Solutions Company ABIGO Medical AB

                            Details : ABIGO Medical has leading innovations in advanced wound care that reduce the spread of bacteria without increasing resistance to antibiotics.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 27, 2020

                            Lead Product(s) : Dialkylcarbamoylchloride,Inapplicable

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Recipient : Abigo Medical AB

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth